tradingkey.logo

Tenax Therapeutics Inc

TENX
View Detailed Chart

6.160USD

-0.060-0.96%
Market hours ETQuotes delayed by 15 min
24.46MMarket Cap
LossP/E TTM

Tenax Therapeutics Inc

6.160

-0.060-0.96%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.96%

5 Days

+1.82%

1 Month

+6.02%

6 Months

+3.53%

Year to Date

-0.48%

1 Year

+100.10%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 4 analysts
STRONG BUY
Current Rating
20.333
Target Price
226.90%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

552
Total
5
Median
6
Average
Company name
Ratings
Analysts
Tenax Therapeutics Inc
TENX
4
CRISPR Therapeutics AG
CRSP
29
Intellia Therapeutics Inc
NTLA
28
Ionis Pharmaceuticals Inc
IONS
27
Exact Sciences Corp
EXAS
27
IQVIA Holdings Inc
IQV
25
1
2
3
...
111

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Buy
Sell(3)
Neutral(2)
Buy(6)
Indicators
Sell(2)
Neutral(2)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
0.062
Buy
RSI(14)
63.418
Neutral
STOCH(KDJ)(9,3,3)
88.369
Overbought
ATR(14)
0.263
Low Volatility
CCI(14)
95.488
Neutral
Williams %R
12.668
Overbought
TRIX(12,20)
0.251
Sell
StochRSI(14)
55.343
Sell
Moving Average
Sell(1)
Neutral(0)
Buy(5)
Indicators
Value
Direction
MA5
6.212
Sell
MA10
6.123
Buy
MA20
5.982
Buy
MA50
5.930
Buy
MA100
5.904
Buy
MA200
5.802
Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Ticker SymbolTENX
CompanyTenax Therapeutics Inc
CEOMr. Christopher T. (Chris) Giordano
Websitehttp://www.tenaxthera.com/
KeyAI